Core Viewpoint - Alvotech anticipates that potential U.S. tariffs on imported pharmaceuticals will have minimal impact on its product revenues in 2025, estimating the effect of a 10% tariff to be less than 1% of total expected revenues [1][2]. Group 1: Tariff Impact - Alvotech manufactures its biosimilars in Iceland, which currently faces a minimum tariff of 10% on goods imported to the U.S. [1][2] - The estimated impact of a 10% tariff on Alvotech's sales to the U.S. in the second half of 2025 would be less than 1% of expected product revenues [2]. - Customers are responsible for all costs of transport and import duties to the U.S., meaning Alvotech will not bear these costs [1][2]. Group 2: Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a global leader in the biosimilar space [3]. - The company has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), and a pipeline of nine disclosed biosimilar candidates targeting various diseases [3]. - Alvotech has established strategic commercial partnerships across multiple regions, including the U.S., Europe, Japan, and parts of Asia and South America [3].

Core Viewpoint - Alvotech anticipates that potential U.S. tariffs on imported pharmaceuticals will have minimal impact on its product revenues in 2025, estimating the effect of a 10% tariff to be less than 1% of expected total product revenues [1][2]. Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a leader in the biosimilar space by providing high-quality, cost-effective products [3]. - The company has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), and a pipeline of nine disclosed biosimilar candidates targeting various diseases [3]. - Alvotech has established strategic commercial partnerships across multiple regions, including the U.S., Europe, Japan, and parts of South America, Africa, and the Middle East [3]. Tariff Impact Analysis - The company manufactures its biosimilars in Iceland, which currently faces a minimum tariff of 10% on goods imported to the U.S. [1][2]. - According to the company's estimates, the impact of a 10% tariff on U.S. sales in the second half of the year would be less than 1% of expected product revenues in 2025, with costs not borne by Alvotech due to contractual terms [2]. - Looking beyond 2025, the anticipated impact of tariffs is expected to remain a low single-digit percentage of total product revenues, considering future product launches and increased sales [2].

Core Viewpoint - The FDA has approved Teva Pharmaceutical Industries Ltd. and Alvotech's Selarsdi as an interchangeable biosimilar to Johnson & Johnson's Stelara, expanding treatment options for various inflammatory conditions [1][2]. Group 1: Product Approval and Details - Selarsdi is approved for multiple indications, including adult and pediatric psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis, effective from April 30, 2025 [1]. - The approved presentations of Selarsdi include 45 mg/0.5 mL and 90 mg/mL in prefilled syringes, 45 mg/0.5 mL in vials, and 130 mg/26 mL for intravenous infusion [3]. Group 2: Strategic Partnerships and Market Position - Teva and Alvotech entered a strategic partnership in August 2020 to exclusively commercialize five biosimilar candidates, which was later extended to include additional products [4]. - Teva's recent launches of Selarsdi and another biosimilar, along with a robust pipeline, position the company for strong leadership in the biosimilars market [2]. Group 3: Financial Impact and Stock Performance - Following the news of the approval, TEVA stock increased by 2.10% to $16.53, while ALVO stock rose by 0.67% to $8.22 [5]. Group 4: Future Developments - The FDA has accepted Biologics License Applications for three additional biosimilar candidates developed by Alvotech in partnership with Teva, with goal dates for approval in Q4 2025 [6].

Core Insights - Teva Pharmaceuticals and Alvotech announced FDA approval for SELARSDI™ (ustekinumab-aekn) as interchangeable with Stelara® (ustekinumab), effective April 30, 2025, for various conditions including psoriatic arthritis and Crohn's disease [1][7][8] Company Developments - The approval of SELARSDI is seen as a significant advancement for patient access to affordable treatment options, aligning with Teva's strategy to lead in the biosimilars market [2][4] - Teva has launched two biosimilars, SELARSDI and EPYSQLI, and has a robust pipeline of additional biosimilars expected to launch in the coming years [2][4] - Alvotech is expanding its portfolio with two approved biosimilars in the U.S. and three additional biosimilar candidates under FDA review, indicating a strong growth trajectory [2][6] Product Information - SELARSDI is available in multiple presentations, including 45 mg/0.5 mL and 90 mg/mL for subcutaneous injection, and 130 mg/26 mL for intravenous infusion [2][7] - The biosimilar targets the p40 protein, crucial for treating immune-mediated diseases, and is produced using the same cell line and process as Stelara® [3][7] Strategic Partnerships - Teva and Alvotech have a strategic partnership for the exclusive commercialization of biosimilars, which has been extended to include additional products and presentations [4][5] - The partnership allows Teva to leverage its extensive sales and marketing infrastructure while Alvotech manages development and manufacturing [4][5] Market Context - The approval of SELARSDI and other biosimilars is part of a broader trend towards increasing access to biologic treatments, which is essential for lowering healthcare costs [2][4] - The FDA's approval of SELARSDI as interchangeable with Stelara® is expected to enhance competition in the biologics market, benefiting patients and healthcare providers [2][4]

Core Viewpoint - Alvotech is set to release its financial results for Q1 2025 on May 7, 2025, and will hold a conference call on May 8, 2025, to discuss these results and recent business highlights [1]. Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines globally, aiming to be a leader in the biosimilar market by providing high-quality, cost-effective products [3]. - The company has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), which are marketed in multiple global markets [3]. - Alvotech's development pipeline includes nine disclosed biosimilar candidates targeting various conditions such as autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3]. - The company has established a network of strategic commercial partnerships across the United States, Europe, Japan, China, and other regions, enhancing its global reach [3]. Investor Relations - Information regarding the webcast and conference call participation is available on Alvotech's investor website, with the webcast being archived for 90 days post-event [2]. - The company encourages engagement through its investor portal and social media platforms [4].

REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at 8:00 am EDT ...

Group 1 - Alvotech (NASDAQ: ALVO) was previously rated as a "Buy" with shares trading at $12, ending 2024 at approximately $13.5, but has seen a significant decline since mid-February [2] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, product sales forecasts, and detailed financial analyses [2] - The analyst, Edmund Ingham, has over 5 years of experience in biotech, healthcare, and pharma, having compiled detailed reports on over 1,000 companies [2]

Financial Performance - In 2024, the company achieved revenues of $492 million, representing a growth of over 400% compared to the previous year [20][70] - Adjusted EBITDA for 2024 was approximately $108 million, a significant improvement from a loss of $300 million in 2023 [20][69] - Product revenues exceeded milestone revenues for the first time, totaling just over $273 million, an increase of 460% year-on-year [20][66] - Product gross margins improved from negative in Q1 to 45% in Q4, driven by scale, process improvements, and a better product mix [22][67] Business Lines and Market Performance - The company has ten products in advanced development and 18 molecules have passed cell line development, targeting a total addressable market of over $185 billion [12][13] - The launch of AVT02 in the U.S. and AVT04 in Europe were highlighted as significant achievements, with AVT02 capturing about 12% of the total U.S. demand for Humira by the end of 2024 [16][34] - The company expects to launch several new biosimilars in 2025, including AVT03 and AVT06, with anticipated approvals in Q4 2024 [24][78] Strategic Direction and Industry Competition - Alvotech aims to leverage its R&D capabilities and expand its pipeline, with a goal of reaching $1.5 billion in revenues and a 40% to 45% EBITDA margin by 2028 [25][90] - The acquisition of Xbrane's R&D operations in Sweden is expected to enhance the company's development capabilities and attract talent [28][61] - The company is positioned to be first to market with several biosimilars, including those for Cimzia and high-dose Eylea, which are expected to launch in 2028 [30][88] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the growth of biosimilars, particularly in the U.S. market, where they expect significant market share conversion in 2025 [35][36] - The company anticipates a strong performance in 2025, projecting revenues between $570 million and $670 million, representing a 25% year-on-year growth [74][75] - Management highlighted the importance of maintaining a strong supply chain and quality focus to capitalize on market opportunities [40][41] Other Important Information - The company raised over $300 million in capital in 2024, simplifying its capital structure and removing all 2025 maturities [19][72] - Alvotech closed the year with $1.069 billion in debt and $51 million in cash, with plans to achieve free cash flow positive status in 2025 [72][73] Q&A Session Summary Question: Thoughts on Stelara pricing and potential private label deals - Management indicated that it is too early to comment on U.S. pricing for Stelara due to its recent launch, but they are optimistic about market position [100][102] - In Europe, established pricing trends were noted, with expectations of some price pressure as competition increases [101][102] Question: Cadence of milestone revenues and future expectations - Management expressed confidence in achieving milestone revenues in 2025 due to signed contracts and progress in R&D [99][103] - They expect about 75% of milestone revenues to be recognized in the second half of 2025, driven by approvals and launches [104][105]

Financial Performance & Outlook - Total revenues reached $492 million, exceeding the latest guidance, compared to $93 million in 2023, a 427% increase[25,59] - Product revenues were $273 million, surpassing $49 million in 2023, a 462% increase[25,59] - Adjusted EBITDA was $108 million, a significant turnaround from a loss of $291 million in 2023[25,59] - The company anticipates revenues between $570 million and $670 million in 2025, with product revenue contributing $340 million to $410 million and milestone revenues between $230 million and $260 million[67] - The company projects an adjusted EBITDA between $180 million and $260 million in 2025[67] - Alvotech targets approximately $1.5 billion in revenue by 2028[70,77] - Alvotech targets an EBITDA margin of 40-45% by 2028[73,77] Commercial & R&D Updates - SIMLANDI units shipped to the US across both branded and private label channels in 2024 reached 1.3 million, with 60% of those units shipped in Q4 2024[35] - The company has biosimilar approval in 63 markets and has launched in 29 markets[37] - By the end of 2025, investments will enable a total annual capacity of 15 million finished units[42]

Financial Performance - The company incurred significant losses of $231.9 million, $551.7 million, and $513.6 million for the years ended December 31, 2024, 2023, and 2022, respectively, with an accumulated deficit of $2,437.7 million as of December 31, 2024[31]. - The company’s ability to generate cash flow to meet significant debt service obligations is uncertain, which could adversely affect its financial condition[42]. - As of December 31, 2024, the company had cash and cash equivalents of $51.4 million, indicating a stable financial position despite uncertainties[46]. - The company had outstanding indebtedness of $1,068.6 million, consisting of $990.7 million under the Secured Loan Facility and $77.8 million in bank loans[51]. - The company may need to raise substantial additional funding, which could lead to shareholder dilution and restrict operations[45]. - The company may require significant additional funding to obtain regulatory approval and successfully commercialize product candidates, which could lead to dilution of existing shareholders' equity[47]. - The company faces risks related to its substantial indebtedness, which could limit its ability to obtain additional financing and increase vulnerability to adverse economic conditions[52]. Regulatory Challenges - The company faces risks related to regulatory approval processes, which are lengthy and uncertain, potentially impacting the commercialization of product candidates[30]. - The lengthy regulatory approval processes may significantly delay the commercialization of product candidates, impacting the company's ability to generate revenue[80]. - The company faces risks related to the development of biosimilar product candidates, including the need to demonstrate biosimilarity to regulatory authorities[92]. - The transition period following Brexit has created uncertainty that may affect the company's ability to achieve regulatory approval in the UK[84]. - The UK is now considered a third country to the EU, which complicates the regulatory landscape for the company[86]. - The MHRA has introduced new procedures to prioritize access to new medicines, which may impact the company's marketing authorization applications[89]. - The company may incur significant additional expenses due to changes in the regulatory framework in the UK and EEA[90]. - Regulatory approvals may impose limitations on marketing conditions and require additional data generation, potentially increasing costs and delaying commercialization[131]. - The company must maintain various regulatory approvals, and failure to do so could disrupt operations and lead to enforcement actions[161]. - The company faces significant regulatory challenges that could restrict business activities and impact drug development and revenue generation capabilities[163]. Research and Development - The company anticipates significant increases in research and development expenses as it advances product candidates through clinical studies[45]. - Clinical drug development is lengthy and expensive, with potential delays due to public health emergencies or geopolitical events[102]. - The company may incur additional costs or impair its ability to achieve regulatory approval if it fails to complete necessary clinical studies[105]. - Changes in manufacturing processes may require additional studies to demonstrate comparability, potentially delaying regulatory approval[106]. - The company relies on participant recruitment for clinical trials, and any withdrawal could delay the development or approval of product candidates[115]. Manufacturing and Supply Chain - The company acquired the Reykjavik manufacturing and research facility for $48.8 million, which is secured by a first priority mortgage[70]. - Manufacturing of product candidates is dependent on third-party CMOs, and any failure to provide sufficient quantities or quality could adversely affect the company's operations[145]. - The manufacturing process is susceptible to variability without well-controlled master and working cell banks, which are essential for consistent high-quality biologic medicine production[98]. - Compromised cell banks could prevent the company from producing usable products, impacting its ability to meet market demand[99]. - The company is subject to risks from natural disasters affecting its manufacturing facility in Reykjavik, Iceland, which could disrupt operations[158]. - Regulatory compliance and quality assurance are critical, and any failure by third-party manufacturers to comply with cGMP regulations could lead to significant delays in product approval[146]. Competition and Market Dynamics - The company is exposed to competition from other biosimilars and reference products, which could limit market penetration and revenue potential[176]. - The company faces intense competition from established pharmaceutical companies with greater resources, which may hinder its ability to commercialize products successfully[182]. - Competitors may develop improved versions of reference products, potentially reducing the market for the company's biosimilar candidates[178]. - The company may face price competition from other biosimilars, which could adversely affect market share and revenue[204]. - The uncertainty of third-party coverage and reimbursement could limit the company's ability to market products and generate revenue[194]. - The company expects pricing pressures due to managed healthcare trends and legislative changes[198]. Intellectual Property and Legal Risks - The company may face claims of patent infringement from third parties, which could lead to substantial legal expenses and potential damages[207]. - There is uncertainty regarding the identification and interpretation of relevant patents, which may adversely affect the company's ability to develop and market its products[216]. - The company has not completed a freedom-to-operate analysis for products in its future biosimilar pipeline, leaving potential risks from unexpired patents[208]. - Patent litigation could result in significant costs and distract management from core business operations, potentially harming the company's financial condition[213]. - The company may be subject to claims from non-practicing entities, which could lead to costly litigation and impact its market operations[210]. - The issuance of "submarine" patents could delay the company's ability to introduce biosimilar candidates into the market[215]. - The company may incur substantial expenses defending against patent infringement claims, which could hinder its research and development efforts[220]. Strategic Partnerships and Collaborations - The company has entered into collaboration agreements with Teva and STADA for the development and commercialization of AVT02 and AVT04 in the U.S. and Europe, respectively[190]. - The company does not have direct sales capabilities and relies on partners for commercialization, which could adversely affect revenue if partners do not perform adequately[153]. - Collaborations with third parties for product development may be terminated, impacting the company's ability to commercialize its product candidates[151].